VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DHRDanaher Corporation
$230.25$161.9B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDHRAnalysis
DHR logo

Danaher Corporation (DHR) Research Brief

Wall Street consensus, price target range, and equity research thesis

Buy43 Analyst Coverage
Consensus Target
$239+3.7% Upside
Current: $230.25
Analyst Range
Low $195High $275
12-Month High/Low Spread
Ratings Mix
31 Buy·11 Hold·1 Sell
Earnings & Valuation
EPS Beat 9.9%
Forward P/E: 26.8x

Executive Summary & Research Take

Wall Street currently rates DHR buy with a 12-month price target of $239 (+3.7% upside). The sections below cover the bull case, key risks, and latest earnings context for Danaher Corporation.

Recent Analyst Actions

DHR Analyst Upgrades & Price Target Changes

8 of 8 analysts raised targets. Recent price target changes and ratings for DHR.

Updated Nov 2026
FirmActionRatingPrice Target
CitigroupRaisedBuy$230$270
BarclaysRaisedOverweight$255$260
JP MorganRaisedOverweight$250$270
TD CowenRaisedBuy$255$270
StifelRaisedBuy$220$260
BairdRaisedOutperform$246$254
Morgan StanleyRaisedOverweight$220$240
TD CowenRaisedBuy$236$255

Analyst ratings update weekly. Get DHR's next verdict in your inbox.

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

Analyst Research Summary

Investment Thesis: Bull Case & Risk Factors

A structured look at the bull case, the risks, and the most recent earnings execution for DHR.

Current setup

DHR beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.

Bull Case

What keeps the long thesis intact

  • Life sciences leadershipDanaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology.
  • Bioprocessing recovery momentumThe company has shown strong bioprocessing recovery, contributing to a 14.14% stock price appreciation since previous coverage.
  • Conservative guidance upsideManagement's conservative 2026 guidance sets a baseline that could be exceeded, with projected high-single-digit EPS growth and 3-6% core revenue growth.
  • Aggressive share buybacksDanaher's aggressive buyback strategy supports shareholder value and stock price appreciation.
  • Healthcare innovation focusThe company's focus on solving global health challenges through biotechnology and diagnostics positions it for long-term growth.
  • Resilient fundamentalsDanaher's fundamentals remain resilient, underpinned by its leading position in diagnostics and life sciences.
  • Connected medical equipmentDanaher's solutions in connected medical equipment streamline workflows in dental, lab automation, and radiology, enhancing efficiency.

Wall Street rates DHR buy, giving the bull case institutional backing from 43 analysts.

Watch Out For

What can break the setup quickly

No AI-generated risk factors available for DHR yet.

Watch whether new negative commentary on DHR points to these structural risks or is simply reacting to short-term price moves.

DHR Earnings Reaction — What the Last Quarter Showed

Last Quarter

EPS
$2.11 vs $1.92 est.Beat 9.9%
Revenue
$6.6B vs $6.6B est.Miss 0.1%
Consensus & Technical Research Suite
Open DHR Terminal

DHR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

DHR Stock Overview

Stock snapshot, live price chart, key ratios, and company profile.

View Overview

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DHR — Frequently Asked Questions

Quick answers to the most common questions about buying DHR stock.

What is the analyst consensus on DHR?
Verdict

DHR appears fairly valued near today's $230.25 — the consensus rating is "Buy" with a $239 target (+3.7%). This is informational only — verify the data and consider your own risk tolerance before deciding.

What are recent analyst rating changes for DHR?
Timing

Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +3.7% upside to the $239 target. In the past 30 days, 8 of 8 covering analysts raised their price targets — a bullish signal.

What is the price target for DHR stock?
Price Target

DHR's consensus 12-month price target is $239, set by 43 Wall Street analysts. The bull case high is $275 and the bear case low is $195. From the current price of $230.25, this implies +3.7% upside.

Is DHR overvalued or undervalued?
Valuation

DHR appears fairly valued — the $239 consensus target is roughly in line with today's $230.25 (+3.7%). It trades at a forward P/E of 26.8x. Targets range from $195 (bear) to $275 (bull), reflecting different assumptions about growth and margins.

What were DHR's latest earnings results?
Earnings

DHR reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $239 target. Consider position sizing rather than going all-in pre-print.

What is the bull case for DHR?
Coverage

Of 43 analysts covering Danaher Corporation (DHR): 1 Strong Buy, 30 Buy, 11 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $239 (range $195–$275). Bullish analysts outnumber bearish by more than 2-to-1.

What are the risks of investing in DHR?
Risks

1 of the 43 analysts covering DHR rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Danaher Corporation.

Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.